Glaxo Gives Up One Of Three Patents For Avandia In China

Law360 (August 18, 2004, 12:00 AM EDT) -- U.K. drug maker GlaxoSmithKline has abandoned its claim to a Chinese patent for a component of its popular diabetes drug Avandia, but is holding on to two other patents on the drug in an escalating battle with Chinese generic makers.

Glaxo dropped a countersuit against Chinese drugmakers, which challenged its patent for rosiglitazone, one of three patented ingredients in Avandia, a spokeswoman for the company told local media and newswires.

She did not give a reason for the decision, but the lawyer for the Chinese companies...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.